Hasty Briefsbeta

Bilingual

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies - PubMed

3 hours ago
  • #CAR T-cell therapy
  • #cutaneous adverse events
  • #hematologic malignancies
  • Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies
  • No competing interests declared by the authors
  • Reference to ABECMA (idecabtagene vicleucel) package insert by Bristol-Myers Squibb Company